Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Organogenesis Holdings Inc. (ORGO:NASDAQ), powered by AI.
Organogenesis Holdings Inc. is currently trading at $2.40. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Organogenesis Holdings Inc. on Alpha Lenz.
Organogenesis Holdings Inc.'s P/E ratio is 8.2.
“Organogenesis Holdings Inc. trades at a P/E of 8.2 (undervalued) with solid ROE of 9.0%.”
Ask for details →Organogenesis Holdings Inc. is a prominent entity in the biotechnology field, engaged in the development, manufacture, and services related to regenerative medicine products. The company's primary focus is on products that help solve complex medical conditions by harnessing the body's natural ability to repair and regenerate tissue. These products are particularly significant in the areas of advanced wound care and surgical and sports medicine. By offering bioactive and acellular biomaterials, Organogenesis plays a crucial role in speeding up the healing process for patients and enhancing clinical outcomes. Organogenesis Holdings Inc. operates its business through a comprehensive distribution network which provides its solutions to healthcare providers across the United States and internationally. The company's efforts in the regenerative medicine space have significant implications for sectors such as hospitals, clinics, and specialized centers dealing with wound care and surgical applications. By contributing to advancements in tissue repair, the firm's products hold a noteworthy position in the healthcare market, impacting both medical practices and patient care worldwide.
“Organogenesis Holdings Inc. trades at a P/E of 8.2 (undervalued) with solid ROE of 9.0%.”
Ask for details →Organogenesis Holdings Inc. (ticker: ORGO) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 869 employees. Market cap is $304M.
The current price is $2.4 with a P/E ratio of 8.21x and P/B of 0.7x.
ROE is 9.04% and operating margin is 9.92%. Annual revenue is $563M.